source
- Cloudbreak Pharma’s Phase 3 Eye Drop Shows Significant Benefit in Pterygium TrialCloudbreak Pharma reported that its phase 3 trial of CBT-001, a multi‑kinase inhibitor eye drop for pterygium, met both co‑primary endpoints. The study compared two doses of CBT-001 given twice da…
- Minghui licenses sub-q TED drug to Japan's ASKA in up to $440 million dealMinghui Pharmaceutical of China has signed a licensing agreement with Japan's ASKA Pharmaceutical, granting exclusive rights to develop and sell its late‑stage thyroid eye disease (TED) candidate i…